Drug intelligence / Profile preview

Likzone

Development stage
Approved
Lead developer
Uni-Tech Pharmaceutical
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Likzone is a generic brand of ceftriaxone sodium, a third-generation cephalosporin antibiotic developed and manufactured by Uni-Tech Pharmaceutical (Pvt.) Ltd. in Pakistan. It is a broad-spectrum bactericidal agent that works by inhibiting bacterial cell wall synthesis. Specifically, it binds to and inactivates penicillin-binding proteins (PBPs), which are enzymes essential for the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. This leads to cell wall instability and subsequent bacterial lysis. Likzone is approved for the treatment of a wide range of infections caused by susceptible organisms, including lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, urinary tract infections, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, and meningitis. It is also used for surgical prophylaxis.

Brand names
Likzone
Other names
ceftriaxone sodium
02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Likzone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Likzone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call